Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431668 | 0.80 | NPSR1 (0.40) | KMT2AMEN1BRD4PNPNPSR1 | |
| SCHEMBL11097769 | 0.72 | MEN1 (0.59) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL23840126 | 0.70 | NOS3 (0.39) | KMT2AMEN1BRD4HPGDALDH1A1 | |
| SCHEMBL6581511 | 0.69 | MEN1 (0.51) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL3859120 | 0.68 | PARP1 (0.56) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL31460305 | 0.68 | MEN1 (0.54) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL21733507 | 0.68 | MEN1 (0.54) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL30834488 | 0.68 | MEN1 (0.54) | KMT2AMEN1BRD4PNPHPGD | |
| SCHEMBL29697758 | 0.67 | GRIA1 (0.46) | KMT2AMEN1BRD4ALDH1A1KDM4E | |
| SCHEMBL7846846 | 0.67 | BRD4 (0.40) | KMT2AMEN1BRD4NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251493-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | SEIWERT SCOTT D (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037259-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | KMT2A 3177/4885MEN1 4563/4885BRD4 199/4885 |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | KMT2A 2360/4885MEN1 4762/4885BRD4 700/4885 |
| US-20120251493-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | KMT2A 3200/4885MEN1 4428/4885BRD4 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.